December 2022

GenAhead Bio licenses CRISPR/Cas9 from Broad Institute

GenAhead Bio Incorporated (“GenAhead”) announced today the signing of a non-exclusive commercial research tool and services license agreement to CRISPR / Cas9 genome editing technology from the Broad Institute of MIT and Harvard. GenAhead began operations in 2018 as a spin-out from Takeda Pharmaceutical Company Limited and has since leveraged the latest CRISPR / Cas9 […]

Read more